Featured Research

from universities, journals, and other organizations

Study Shows PET/CT Imaging Can Help Diagnose And Define Occult Recurrent Cancer

Date:
December 29, 2004
Source:
Society Of Nuclear Medicine
Summary:
Combined positron emission tomography and computerized tomography (PET/CT) can help diagnose occult (hidden) recurrent cancer, possibly a cancer patient's greatest post-treatment fear, report a team of Israeli physicians in the December issue of the Society of Nuclear Medicine's "Journal of Nuclear Medicine."

RESTON, Va. -- Combined positron emission tomography and computerized tomography (PET/CT) can help diagnose occult (hidden) recurrent cancer, possibly a cancer patient's greatest post-treatment fear, report a team of Israeli physicians in the December issue of the Society of Nuclear Medicine's "Journal of Nuclear Medicine."

Related Articles


PET and CT scans are standard imaging tools that allow clinicians to pinpoint the location of cancer within the body before making treatment recommendations. PET/CT involves sequential PET and CT imaging on the same device, allowing for simultaneous acquisition of functional (PET) and anatomical (CT) data. "PET/CT was found to indicate the presence of new malignancy and also precisely localize and define the extent of disease" in patients in whom recurring cancer was suspected, explained lead author and SNM member Ora Israel, M.D.

The physicians asked the question, "Is FDG-PET/CT Useful for Imaging and Management of Patients With Suspected Occult Recurrence of Cancer?" Their study points to an affirmative answer, said Israel, who also noted the need for these initial results to be confirmed in large studies with more homogenous patient populations. The research team studied 36 cancer patients for whom blood tests showed increasing levels of serum cancer markers during follow-up.

"PET/CT was the only test that showed whether recurrent tumors were indeed present," and since anatomic information was obtained, the type of treatment that should be applied could be determined, she said. "This is clinically important, since no treatment could be planned in these patients without the benefit of this combined test," added Israel, who is with the department of nuclear medicine at Rambam Medical Center and the B. Rappaport School of Medicine, Technion, Israel Institute of Technology, both in Haifa, Israel.

"If these results are confirmed by larger studies in patients with different types of malignant tumors, PET/CT may potentially be used in the future as the first imaging modality in this group of patients," Israel said. "In some of these patients, further invasive diagnostic procedures may not be needed, and the treating physicians may proceed directly with the appropriate treatment strategy," she added.

Israel noted that PET/CT is already playing a major role in a large variety of clinical indications in cancer patients. "The clinical dilemma of a suspicion of cancer raised by abnormal blood tests may be solved, and management of this patient group may be optimized by this imaging modality," said Israel. The study produced "important and very promising results," said Israel, "since they showed not only improved diagnostic accuracy of PET/CT over PET, as was initially hypothesized, but also the impact of patient management."

###

"Is FDG-PET/CT Useful for Imaging and Management of Patients With Suspected Occult Recurrence of Cancer?" was written by Ora Israel, M.D., Department of Nuclear Medicine, Rambam Medical Center, and the B. Rappaport School of Medicine, Technion, Israel Institute of Technology, both in Haifa, Israel; Maya Mor, M.D., Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel; Luda Guralnik, M.D., Department of Diagnostic Imaging, Rambam Medical Center, Haifa, Israel; Nirit Hermoni, M.D., Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel; Diana Gaitini, M.D., the B. Rappaport School of Medicine, Technion, Israel Institute of Technology and the Department of Diagnostic Imaging, Rambam Medical Center, both in Haifa, Israel; Rachel Bar-Shalom, M.D., Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel; Zohar Keidar, M.D., Ph.D., Department of Nuclear Medicine, Rambam Medical Center, and the B. Rappaport School of Medicine, Technion, Israel Institute of Technology, both Haifa, Israel; and Ron Epelbaum, M.D., the B. Rappaport School of Medicine, Technion, Israel Institute of Technology, and the Department of Oncology, Rambam Medical Center, both in Haifa, Israel. Authors Israel, Bar-Shalom and Keidar are SNM members.

The Society of Nuclear Medicine is an international scientific and professional organization of more than 15,000 members dedicated to promoting the science, technology and practical applications of nuclear medicine. The SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.


Story Source:

The above story is based on materials provided by Society Of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society Of Nuclear Medicine. "Study Shows PET/CT Imaging Can Help Diagnose And Define Occult Recurrent Cancer." ScienceDaily. ScienceDaily, 29 December 2004. <www.sciencedaily.com/releases/2004/12/041220010556.htm>.
Society Of Nuclear Medicine. (2004, December 29). Study Shows PET/CT Imaging Can Help Diagnose And Define Occult Recurrent Cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2004/12/041220010556.htm
Society Of Nuclear Medicine. "Study Shows PET/CT Imaging Can Help Diagnose And Define Occult Recurrent Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/12/041220010556.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Matter & Energy News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Will New A350 Help Airbus Fly?

Will New A350 Help Airbus Fly?

Reuters - Business Video Online (Dec. 22, 2014) Qatar Airways takes first delivery of Airbus' new A350 passenger jet. As Joel Flynn reports it's the planemaker's response to the Boeing 787 Dreamliner and the culmination of eight years of development. Video provided by Reuters
Powered by NewsLook.com
Man Parachutes Off Lawn Chair Airlifted By Helium Balloons

Man Parachutes Off Lawn Chair Airlifted By Helium Balloons

Buzz60 (Dec. 22, 2014) A BASE jumper rides a lawn chair, a shotgun, and a giant bunch of helium balloons into the sky in what seems like a country version of the movie 'Up." Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Space & Time

Matter & Energy

Computers & Math

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins